Nonselective beta-blockers (NSBB) have been used in portal hypertension for nearly 4 decades. Numerous studies demonstrate carvedilol to be more effective than propranolol in reducing HVPG.
1,2Carvedilol, through alpha 1 blockade also reduces intrahepatic resistance. However, as with all NSBB, carvedilol results in dose related arterial hypotension, particularly in advanced cirrhosis and ascites. 3,4 Carvedilol is metabolised by the liver and has 2 stereoisomers, R-carvedilol and S-carvedilol. Liver disease results in increased availability of both stereoisomers, with much greater nonselective betablockade than in healthy individuals. 5 Studies clearly demonstrate that carvedilol 12.5 mg daily is sufficient for optimal reduction in hepatic venous pressure gradient (HVPG), with higher doses risking more side effects, in particular hypotension, without a therapeutic benefit. 2,6 However, does a lower dose offer sufficient efficacy while minimising side effects?The paper by Schwarzer et al aims to answer this question in the context of primary prophylaxis. 7 It is a well designed, dose-